Fatty Liver Formation in Patients with Breast Cancer on Tamoxifen Therapy in Iraqi Female

This is a prospective, hospital based, case-control study conducted at Oncology and  Nuclear medicine specialist Hospital, in Nineveh province in Iraq during the period from February 2018 to November 2018, to determine the prevalence of fatty liver formation in tamoxifen treatments by ultrasonographic examinations. Fifty- patients receiving tamoxifen were involved in this study, 11 of these were premenopausal from the premenopausal subgroup patients14 (28%) their age (25-44) years in which 10 of them were Grade I fatty liver & 1 case was Grade II fatty liver , no cases seen had Grade III , and 32 patients were postmenopausal were from post menopausal subgroup patients  36 (72%) range their age (45-78) years, in which 16 of them had fatty liver Grade I, & 16 of them had fatty liver Grade II , no cases seen had Grade III, The duration of tamoxifen was range (>6–72) months, with 33control case, which were 24 case premenopause and 9 case postmenopause which had 3 of them were grade II in premenopausal age group , while 3 cases were postmenopausal patients age group in which 1 case was Grade I fatty liver & 2 cases were Grade II